Celcuity (CELC) Price & Analysis

Compare

463 Followers

CELC Stock Chart & Stats

$101.14

-$0.35(-2.63%)

At close: Jan 08 4:00 PM EST

$101.14

-$0.35(-2.63%)

Day’s Range― - ―

52-Week Range$7.58 - $112.64

Previous CloseN/A

Volume14.25K

Average Volume (3M)982.33K

Market Cap

$4.68B

Enterprise Value$2.22B

Total Cash (Recent Filing)$454.98M

Total Debt (Recent Filing)$320.35M

Price to Earnings (P/E)―

Beta0.34

Next Earnings

Mar 19, 2026

EPS Estimate

-1.04

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.92

Shares Outstanding46,271,260

10 Day Avg. Volume1,083,752

30 Day Avg. Volume982,331

Financial Highlights & Ratios

PEG Ratio-0.89

Price to Book (P/B)4.47

Price to Sales (P/S)0.00

P/FCF Ratio-6.17

Enterprise Value/Market Cap0.47

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-29.45K

Enterprise Value/Ebitda-16.35

Forecast

1Y Price Target

$105.25

Price Target Upside4.06% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

EPS Forecast (FY)-3.86

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessCelcuity's Phase 3 VIKTORIA-1 trial showed detailed results that exceeded expectations with a favorable overall survival rate for the PIK3CA WT cohort.

Financial PositionCELC has $455M in cash and seems well capitalized ahead of a commercial launch for gedatolisib.

Regulatory ApprovalThe FDA has agreed to accept the NDA application for approval of gedatolisib as a therapy for advanced breast cancer with wild-type PIK3CA.

Bears Say

Market CompetitionThe company could be tasked to compete against some of the large cap pharma companies with proven commercial infrastructure in breast cancer.

Market SentimentShort interest in Celcuity's stock is relatively high at 28.2% of the float, indicating potential market skepticism.

Valuation RisksCurrent valuation assumes premium pricing, and if payors extract a higher discount – leading to a lower gross to net pricing – the stock could rerate if either the adoption or the revenue per patient is less than expected.

Celcuity News

5 Stocks That Moved the Most in 2025 – What Lies Ahead

The year 2025 has been anything but quiet, and a handful of mid‑ and large‑cap names have delivered...

11h ago

RGC

ABVX

Wells Fargo bullish on Celcuity, initiates with an Overweight

As previously reported, Wells Fargo initiated coverage of Celcuity (CELC) with an Overweight rating and $126 price target...

12d ago

CELC

Celcuity initiated with an Overweight at Wells Fargo

Wells Fargo initiated coverage of Celcuity (CELC) with an Overweight rating and $126 price target Published first on...

12d ago

CELC

Short Report: Core Scientific short interest at record high

Welcome to this week’s installment of “The Short Interest Report” – The Fly’s weekly recap of short interest...

1M ago

CAR

CELC

Celcuity Submits NDA for Gedatolisib to FDA

An update from Celcuity ( ($CELC) ) is now available. On November 17, 2025, Celcuity Inc. announced the...

1M ago

CELC

Celcuity submits gedatolisib new drug application to the FDA

Celcuity (CELC) announced the completion of the submission of its new drug application to the FDA for gedatolisib...

1M ago

CELC

Celcuity initiated with an Outperform at Wolfe Research

Wolfe Research initiated coverage of Celcuity (CELC) with an Outperform rating and $110 price target Fresh off a...

1M ago

CELC

Block upgraded, Dell downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

1M ago

GAP

HPE

Celcuity downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright downgraded Celcuity (CELC) to Neutral from Buy with a price target of $94, up from $77....

1M ago

CELC

Celcuity’s Gedatolisib: A Promising Standard for 2L Breast Cancer Treatment

TD Cowen analyst Tara Bancroft has maintained their bullish stance on CELC stock, giving a Buy rating on...

1M ago

CELC

Celcuity Inc. Earnings Call: Strong Progress Amid Challenges

Celcuity Inc. (($CELC)) has held its Q3 earnings call. Read on for the main highlights of the call....

1M ago

CELC

Celcuity price target raised to $108 from $96 at Craig-Hallum

Craig-Hallum analyst Chase Knickerbocker raised the firm’s price target on Celcuity (CELC) to $108 from $96 and keeps...

1M ago

CELC

Celcuity price target raised to $115 from $68 at Stifel

Stifel raised the firm’s price target on Celcuity (CELC) to $115 from $68 and keeps a Buy rating...

1M ago

CELC

Celcuity’s Strategic Advances and Robust Financials Justify Buy Rating

Analyst Gil Blum from Needham maintained a Buy rating on Celcuity and keeping the price target at $95.00....

1M ago

CELC

CELC FAQ

What was Celcuity Inc.’s price range in the past 12 months?

Celcuity Inc. lowest stock price was $7.58 and its highest was $112.64 in the past 12 months.

What is Celcuity Inc.’s market cap?

Celcuity Inc.’s market cap is $4.68B.

When is Celcuity Inc.’s upcoming earnings report date?

Celcuity Inc.’s upcoming earnings report date is Mar 19, 2026 which is in 85 days.

How were Celcuity Inc.’s earnings last quarter?

Celcuity Inc. released its earnings results on Nov 12, 2025. The company reported -$0.92 earnings per share for the quarter, beating the consensus estimate of -$1.019 by $0.099.

Is Celcuity Inc. overvalued?

According to Wall Street analysts Celcuity Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Celcuity Inc. pay dividends?

Celcuity Inc. does not currently pay dividends.

What is Celcuity Inc.’s EPS estimate?

Celcuity Inc.’s EPS estimate is -1.04.

How many shares outstanding does Celcuity Inc. have?

Celcuity Inc. has 46,271,260 shares outstanding.

What happened to Celcuity Inc.’s price movement after its last earnings report?

Celcuity Inc. reported an EPS of -$0.92 in its last earnings report, beating expectations of -$1.019. Following the earnings report the stock price went up 0.998%.

Which hedge fund is a major shareholder of Celcuity Inc.?

Currently, no hedge funds are holding shares in CELC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Celcuity Stock Smart Score

Outperform

Fundamentals

Return on Equity

-122.04%

Trailing 12-Months

Asset Growth

74.34%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Celcuity Inc.

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Celcuity (CELC) Earnings & Revenues

Historic Earnings Reports

CELC Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a strong position for Celcuity, with significant clinical and regulatory progress, a solid financial foundation, and promising market potential. However, the increased financial loss and regulatory uncertainties present challenges that need to be addressed.View all CELC earnings summaries

CELC Stock 12 Month Forecast

Average Price Target

$105.25

▲(4.06% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","127":"$127","37.75":"$37.8","67.5":"$67.5","97.25":"$97.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":126,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$126.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":105.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$105.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":94,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$94.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,37.75,67.5,97.25,127],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,98.48,100.59692307692308,102.71384615384616,104.83076923076923,106.94769230769231,109.0646153846154,111.18153846153847,113.29846153846154,115.41538461538462,117.5323076923077,119.64923076923077,121.76615384615386,123.88307692307693,{"y":126,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,98.48,99.00076923076924,99.52153846153847,100.0423076923077,100.56307692307692,101.08384615384615,101.60461538461539,102.12538461538462,102.64615384615385,103.16692307692308,103.6876923076923,104.20846153846153,104.72923076923077,{"y":105.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,98.48,98.13538461538462,97.79076923076923,97.44615384615385,97.10153846153847,96.75692307692307,96.41230769230769,96.06769230769231,95.72307692307693,95.37846153846154,95.03384615384616,94.68923076923078,94.34461538461538,{"y":94,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.63,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.09,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.95,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.43,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.29,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.8,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.62,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.49,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.91,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.58,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.22,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.16,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.48,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >